Adjunctive cholestyramine therapy for thyrotoxicosis*
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: OBJECTIVE Initial therapy of thyrotoxicosis usually includes beta‐blockade for symptom relief and thionamides to block new thyroid hormone synthesis. In view of the increased enterohepatic circulation of thyroxine (T4) and triiodothyronine (T3) in thyrotoxicosis, we proposed that cholestyramine, an anion exchange resin which binds iodothyronines, when used adjunctively with thionamides and a beta‐blocker, would lower serum iodothyronine levels faster than would standard therapy alone. DESIGN A double blind placebo‐controlled cross‐over design was used with patients randomly assigned to either the treatment or control groups. They received their initial treatment for two weeks (Phase 1) followed by a one‐week washout period, and then crossed to the opposite treatment for two weeks (Phase 2). Standard therapy included atenolol 50 mg daily, individualized dosages of methimazole and either 4 g of cholestyramine or 4 g of placebo powder four times per day. PATlENTS Fifteen patients with thyrotoxicosis (14 Graves' disease, 1 toxic adenoma) participated in this study. MEASUREMENTS Total and free thyroxine and triiodothyronine, as well as thyroid‐stimulating immunoglobulin and thyrotrophin‐binding inhibitory immunoglobulin, were measured weekly. RESULTS Seven patients received cholestyramine and eight patients received placebo during Phase 1. A more rapid decline in all thyroid hormone levels was seen in the cholestyramine‐treated group (F= 4–7, P >0.01) than in the placebo group (F= 2–3.1, P= 0 05). In Phase 2, the eight patients who received cholestyramine showed an additional decline in free thyroxine from weeks one to two, but the overall rate of decline in hormone levels was not different between the groups. Immunoglobulin levels remained unaffected regardless of group, treatment, or time. CONCLUSIONS We conclude that cholestyramine is a safe and effective adjunctive agent in the treatment of thyrotoxicosis and that its greatest efficacy may be during the first few weeks of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The influence of cholestyramine on thyroxine absorption
Northcutt, R. C. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160100047012 · Cited by 144 · cited 1×
“In other experiments in rats (Northcutt et al., 1969), it was found that only 2.”
Background
Cited by
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“Cholestyramine binds thyroid hormones in the gut during their enterohepatic recirculation and has been used to treat hyperthyroidism, mostly in combination with other drugs (487,488).”
BackgroundAlexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Thyrotoxicosis and Thyroid Storm
Nayak, B., & Burman, K. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.09.008 · Cited by 394
Self-citationDiagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 296
Metadata
- Authors
- Solomon, B. L., Wartofsky, L., & Burman, K. D.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1993-01
- Volume
- 38
- Issue
- 1
- Pages
- 39-43
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2140821923
- Cited by
- 83
- References
- 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive cholestyramine therapy for thyrotoxicosis*. https://app.cochat.ai/papers/10.1111/j.1365-2265.1993.tb00970.x
- The paper
- Solomon, B. L., Wartofsky, L., & Burman, K. D. (1993). Adjunctive cholestyramine therapy for thyrotoxicosis*. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.1993.tb00970.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.